🔴 Problem Identified
Europe faces a structural funding gap for high-risk, breakthrough-innovation startups, particularly academic spinouts with long commercialization timelines. Traditional VC structures now prioritize safe bets, leaving transformative technologies without access to patient, risk-tolerant capital.
💡 Proposed Solution
Create an online investment platform that aggregates patient capital (from family offices, pension funds, corporates, and wealthy individuals) into 15-20 year funds, explicitly dedicated to funding deeptech, hard science, and moonshot projects across Europe. The platform offers rigorous technical due diligence, matches investors with academic spinouts, and provides post-investment operational support. Investors are incentivized through asymmetric upside potential and co-investment opportunities...
Register to read the full solution →
Market Size
Medium
Difficulty
High
Time to MVP
6+ months
Investment
High
Unlock Full Analysis
Get competitor analysis, cost breakdowns, implementation roadmaps, and AI-powered next steps.
Create Free AccountAlready have an account? Log in
Quick Overview
Target Audience
Academic spinouts, deeptech startups, research institutions, patient capital providers (family offices, pension funds, HNWI, corporates)
Revenue Potential
Up to €25M from fees
Competition
Low
Key Advantage
Focus on long fund lifecycles, rigorous academic partnership networks, investment products tailored for patient capital,...